drugset / Trial / NCT02834507

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

NCT02834507

Phase 2 Completed 19 enrolled Bial - Portela C S.A.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine the effect of two different multiple-dose regimens of nebicapone in comparison to placebo and entacapone 200 mg on the pharmacokinetics of levodopa in Parkinson's Disease (PD) patients.

Timeline

Start
2005-03
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entacapone Small molecule 200 mg
Subject Nebicapone Small molecule 75 mg
Subject Nebicapone Small molecule 150 mg
Background Levodopa Small molecule

Indications